Acumen Pharmaceuticals Inc

ABOS | $3.53 -5.62% -5.5% 220K

(0.0% 1d) (-11.3% 1m) (-3.3% 1y) (0.0% 2d) (0.0% 3d) (-4.9% 7d) (16.74% volume)
Earnings Calendar: 2024-03-25
Market Cap: $ 212,081,616
https://www.acumenpharm.com
Sec Filling | Patents | 2021 employees

Acumen is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target amyloid-beta oligomers, (AβOs), which Acumen believes to be a key underlying cause of Alzheimer’s disease, or AD. Acumen is currently focused on advancing a targeted immunotherapy drug candidate, ACU193, to establish proof of mechanism in early AD patients. Acumen initiated its Phase 1 clinical trial of ACU193 in the second quarter of 2021 with the objective to evaluate its safety and tolerability and explore its pharmacokinetics and target engagement. This trial is currently enrolling patients with mild cognitive impairment and mild dementia due to AD. ACU193 Phase 1 data intended to evaluate safety and tolerability and demonstrate clinical proof of mechanism are expected by year end 2022.

alzheimer alzheimer’s

add to watch list Paper trade email alert is off

Alzamend Neuro Inc

ALZN | $0.741 -12.82% -10.29% 120K

Professional, Scientific, and T...

(0.0% 1d) (-23.6% 1m) (25.6% 1y) (0.0% 2d) (0.0% 3d) (-15.8% 7d) (254.68% volume)
Earnings Calendar: 2024-03-14
Market Cap: $ 5,088,333
https://alzamend.com/
Sec Filling | Patents | 3 employees

(United States) Alzamend Neuro is a preclinical stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer’s disease. With its product candidates, the company aims to bring treatments or cures to market at a reasonable cost as quickly as possible. Its current pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s. Both of its product candidates are licensed from the University of South Florida Research Foundation, Inc. pursuant to royalty-bearing exclusive worldwide licenses.

treatment msa vaccine t-cell lithium alzheimer neurodegenerative alzheimer’s

add to watch list Paper trade email alert is off

Aerovate Therapeutics Inc

AVTE M | $25.3 0.24% 0.43% 110K

Professional, Scientific, and T...

(0.0% 1d) (-4.1% 1m) (39.4% 1y) (0.0% 2d) (0.0% 3d) (-6.3% 7d) (-19.78% volume)
Earnings Calendar: 2024-03-26
Market Cap: $ 704,858,000
https://www.aerovatetx.com
Sec Filling | Patents | 2021 employees

Aerovate is a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. Aerovate's initial focus is on advancing AV-101, its dry powder inhaled formulation of the drug imatinib for the treatment of pulmonary arterial hypertension, or PAH.

treatment

add to watch list Paper trade email alert is off

Synaptogenix Inc

SNPX | $4.48 -4.41% -4.61% 95K

Professional, Scientific, and T...

(0.0% 1d) (2143.7% 1m) (407.5% 1y) (0.0% 2d) (0.0% 3d) (-6.0% 7d) (15.24% volume)
Earnings Calendar:
Market Cap: $ 121,557,404

Sec Filling | Patents | 5 employees

synaptogenix is a clinical-stage biopharmaceutical company that has historically worked to develop novel therapies for neurodegenerative diseases.

add to watch list Paper trade email alert is off

Century Therapeutics Inc

IPSC | $3.675 -6.01% -6.39% 42K

Professional, Scientific, and T...

(0.0% 1d) (-22.7% 1m) (16.5% 1y) (0.0% 2d) (0.0% 3d) (-4.4% 7d) (-63.42% volume)
Earnings Calendar: 2024-03-14
Market Cap: $ 238,205,647
https://www.centurytx.com/
Sec Filling | Patents | 102 employees

(US) Century Therapeutics, Inc. specializes in adult stem cells to develop curative cell therapy products for cancer that overcome the limitations of first generation cell therapies as well as provides testing and research services.

t-cell cancer

add to watch list Paper trade email alert is off

LegalZoom.com Inc.

LZ | $12.41 -2.21% -2.26% 900K

Professional, Scientific, and T...

(0.0% 1d) (-4.5% 1m) (34.3% 1y) (0.0% 2d) (0.0% 3d) (-1.6% 7d) (-1.57% volume)
Earnings Calendar: 2024-02-22
Market Cap: $ 2,332,252,191
https://www.legalzoom.com
Sec Filling | Patents | 1055 employees

(United States) LegalZoom is a leading online platform for legal and compliance solutions in the United States that is on a mission to democratize law. LegalZoom operates across all 50 states and over 3,000 counties in the United States and has more than 20 years of experience navigating complex regulations and simplifying the legal and compliance process for its customers. Driven by its core value that every business deserves the full protection of the legal system and a simple way to stay compliant with it, LegalZoom helps its customers form and protect their businesses, their ideas and families. In 2020, 10% of all new LLCs and 5% of all new corporations in the United States were formed through LegalZoom, enabling small business owners to apply their energy and passion to their businesses instead of the legal and regulatory complexity required to operate them. In addition to business formations, LegalZoom offers ongoing compliance and tax advice, trademark and copyright filings and estate planning documents to protect small businesses and the families that create them.

energy

add to watch list Paper trade email alert is off

Werewolf Therapeutics Inc

HOWL | $5.475 16.74% 14.34% 260K

Professional, Scientific, and T...

(0.0% 1d) (-8.8% 1m) (120.5% 1y) (0.0% 2d) (0.0% 3d) (3.8% 7d) (-36.7% volume)
Earnings Calendar: 2023-11-09
Market Cap: $ 233,986,121
https://werewolftx.com
Sec Filling | Patents | n/a employees

Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. The company is leveraging its proprietary PREDATOR™ platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE™ molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Its most advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2), and Interleukin-12 (IL-12) INDUKINE molecules for the treatment of solid tumors.The company is continuing preclinical studies for both WTX-124 and WTX-330 and expect to advance each candidate in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor.

cancer immunotherapy msa treatment

add to watch list Paper trade email alert is off